Status:
COMPLETED
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Lead Sponsor:
Allergan
Conditions:
Obesity
Overactive Bladder
Eligibility:
FEMALE
18-75 years
Phase:
PHASE4
Brief Summary
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or p...
Eligibility Criteria
Inclusion
- OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence
- Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).
- Obese
Exclusion
- Chronic kidney failure
- Abdominal bypass surgery for obesity
- Moderate or severe memory impairment
- Uncontrolled narrow angle glaucoma
- Uncontrolled systemic disease
- Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT00932022
Start Date
July 1 2009
End Date
December 1 2011
Last Update
January 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
La Mesa, California, United States